⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from Immune marker spatial distribution and clinical outcome after PD-1 blockade in mismatch repair-deficient, advanced colorectal carcinomas

Bahar Saberzadeh-Ardestani Rondell P. Graham Sara McMahon Eze Ahanonu Qian Shi Crystal Williams Antony Hubbard Wenjun Zhang Andrea Murányi Dongyao Yan Zhaohui Jin Kandavel Shanmugam Frank A. Sinicrope

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S2. (A) Distribution of mean number of PD-1 + cells within 10 μm of a PDL1+ cell in the overall tumor; (B) range of possible cutoff values and corresponding hazard ratios.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Saberzadeh-Ardestani et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523801 https://doi.org/10.1158/1078-0432.27034216

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Immune marker spatial distribution and clinical outcome after PD-1 blockade in mismatch repair-deficient, advanced colorectal carcinomas2024
2Supplementary Figure S1 from Immune marker spatial distribution and clinical outcome after PD-1 blockade in mismatch repair-deficient, advanced colorectal carcinomas2024
3Supplementary Figure S1 from Immune marker spatial distribution and clinical outcome after PD-1 blockade in mismatch repair-deficient, advanced colorectal carcinomas2024
4Data from Immune marker spatial distribution and clinical outcome after PD-1 blockade in mismatch repair-deficient, advanced colorectal carcinomas2024
5Abstract 578: Prediction of PD-1 treatment outcome in mismatch repair deficient metastatic colorectal cancer using a multi-omic approach2024

Spatially resolved multi-region proteomics for prediction of clinical outcome in deficient mismatch repair metastatic colorectal cancer treated with PD-1 blockade.2024
Supplementary Figure S10 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer2024
Supplementary Figure S10 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer2024